HeartBeam to Showcase FDA-Cleared Cardiac Technology at Major September Investor Conferences

HeartBeam Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care, announced that CEO Robert Eno and CFO Timothy Cruickshank will present at three major investor conferences in September. The executives will attend the MDB Investor Summit 2025, HRX Live 2025, and the H.C. Wainwright 27th Annual Global Investment Conference, where they will meet with partners and investors while providing updates on the company's commercialization progress.

The presentations will include demonstrations of HeartBeam's FDA-cleared HeartBeam System, a revolutionary cable-free, credit card-sized device that collects 3D ECG signals for arrhythmia assessment. This technology represents a significant advancement in cardiac care, as it enables the collection of ECG signals from three non-coplanar directions and synthesizes them into a 12-lead ECG, all without the traditional cables and complex equipment typically associated with cardiac monitoring.

The importance of this development lies in its potential to transform cardiac health management by enabling portable monitoring outside medical facilities. Physicians will be able to identify cardiac health trends and acute conditions remotely, directing patients to appropriate care without requiring hospital visits. This technology addresses a critical need in healthcare by providing actionable heart intelligence wherever the patient is located, potentially improving early detection and intervention for cardiac conditions.

HeartBeam's 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, marking a major regulatory milestone. The company's 12-Lead ECG synthesis software is currently under FDA review, which could further expand the technology's clinical applications. With over 20 issued patents related to technology enablement, HeartBeam has established a strong intellectual property foundation for its innovative approach to cardiac monitoring.

The company's participation in these investor conferences, including the H.C. Wainwright 27th Annual Global Investment Conference accessible at https://ibn.fm/iTYHV, demonstrates its commitment to advancing cardiac care technology while engaging with the investment community to support its commercialization efforts. This presentation series comes at a crucial time as the company moves toward broader market adoption of its groundbreaking technology.